Barinthus Biotherapeutics’ (BRNS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

Separately, Alliance Global Partners dropped their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ BRNS opened at $0.99 on Tuesday. The stock’s fifty day moving average price is $1.27 and its two-hundred day moving average price is $1.50. Barinthus Biotherapeutics has a one year low of $0.81 and a one year high of $4.16. The firm has a market cap of $39.08 million, a price-to-earnings ratio of -0.60 and a beta of -0.59.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million for the quarter. During the same period last year, the firm posted ($0.37) EPS. On average, equities analysts anticipate that Barinthus Biotherapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Trading of Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of BRNS. DC Funds LP bought a new stake in shares of Barinthus Biotherapeutics during the 1st quarter worth $1,528,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Barinthus Biotherapeutics in the first quarter valued at about $1,292,000. M&G Plc acquired a new stake in shares of Barinthus Biotherapeutics in the second quarter valued at about $7,276,000. Ipswich Investment Management Co. Inc. acquired a new stake in shares of Barinthus Biotherapeutics in the second quarter valued at about $32,000. Finally, Catalina Capital Group LLC acquired a new stake in Barinthus Biotherapeutics during the second quarter worth approximately $25,000. 25.20% of the stock is currently owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.